[HTML][HTML] Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2023 - nature.com
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - 2022 - pesquisa.bvsalud.org
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir | PREPRINT-BIORXIV loading 1
2 3 +A A -A 3.Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir This article is a …
2 3 +A A -A 3.Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir This article is a …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - …, 2023 - ui.adsabs.harvard.edu
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - bioRxiv, 2022 - biorxiv.org
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful in reducing hospitalization or death due to COVID-19 …
demonstrated to be clinically useful in reducing hospitalization or death due to COVID-19 …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2023 - ideas.repec.org
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
[HTML][HTML] Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2023 - ncbi.nlm.nih.gov
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - 2022 - kms.shanghaitech.edu.cn
29 Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated 30 to be clinically useful against COVID-191, 2. However, as SARS-CoV-2 …
demonstrated 30 to be clinically useful against COVID-191, 2. However, as SARS-CoV-2 …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2022 - europepmc.org
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs. 1, 2). However, because SARS …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Nirmatrelvir, an oral antiviral targeting the 3CL
protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 …
protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 …